MoFo News Item

MoFo Advises ARCH Venture Partners on Its Investment in Erasca

30 Apr 2020

Morrison & Foerster advised ARCH Venture Partners and certain other investors in connection with a Series B financing round it co-led with Cormorant Asset Management totaling $200 million in Erasca, a company on a mission to erase cancer.

Founded in 2018 and headquartered in San Diego, Erasca is advancing multiple programs that shut down key cancer pathways in order to solve oncology’s hardest problems. The company will use the proceeds from the Series B financing round to support the clinical development of multiple promising oncology programs and further advance its in-house drug discovery pipeline.

The MoFo deal team was led by Boston-based corporate partner Ori Solomon, co-chair of the firm’s Emerging Companies + Venture Capital Group, and included ECVC associates Dan Murray and Mike Maroni; technology transactions partner Matt Karlyn and associate Tiffany Quach; and patents partner Janet Xiao and scientific analyst Yujia Sun.

Read the press release.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.